Patents by Inventor David G. Hangauer

David G. Hangauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Doxepin analogs and methods of use thereof
    Patent number: 7411069
    Abstract: The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: August 12, 2008
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, James F. White, Michael Solomon
  • Azepans and methods for making and using same
    Publication number: 20080161556
    Abstract: Disclosed are compounds having the formula: wherein Z1 is an alkylene moiety; Q is a carboxylic acid derivative; and R1 and R2 are the same or different and are selected from the group consisting of alkyl, aryl, alkylcarbonyl, arylcarbonyl, hydroxycarbonyl, and alkoxycarbonyl or R1 and R2, taken together with the nitrogen atom to which they are bound, form a ring. Also disclosed are compounds having the formula: wherein Z1 is an alkylene moiety; Q is a carboxylic acid derivative; and R13 is selected from the group consisting of alkyl and aryl. The compounds can be used to modulate cell proliferation and/or apoptosis, for example, in the treatment of cancers and other proliferative diseases, disorders, and conditions.
    Type: Application
    Filed: December 6, 2007
    Publication date: July 3, 2008
    Inventors: David G. Hangauer, Fengzhi Li, Taher Hegab, Xiang Ling
  • Treatment of CNS disorders using CNS target modulators
    Patent number: 7355042
    Abstract: The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention is directed to the compositions and use of derivatized, histamine antagonists for the treatment of sleep disorders.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: April 8, 2008
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J. M. Mignot, James F. White, Michael Solomon, Kazumi Shiosaki
  • Doxepin analogs and methods of use thereof
    Patent number: 7326721
    Abstract: The invention relates to novel doxepin analog compounds and methods of modulating sleep by administering such compounds, or a pharmaceutically effective salt thereof.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: February 5, 2008
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, James F. White, Michael Solomon
  • CNS target modulators
    Patent number: 7317026
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. More specifically, the invention is directed to derivatized, e.g., ester or carboxylic acid derivatized, doxepins, and analogs thereof, useful for the treatment of sleep disorders.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: January 8, 2008
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J. M. Mignot
  • Bicyclic compositions and methods for modulating a kinase cascade
    Publication number: 20080004241
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 3, 2008
    Inventor: David G. Hangauer
  • Compositions for treating cell proliferation disorders
    Patent number: 7300931
    Abstract: The invention relates to compounds and methods for treating cell proliferation disorders.
    Type: Grant
    Filed: December 28, 2005
    Date of Patent: November 27, 2007
    Assignee: Kinex Pharmaceuticals, LLC
    Inventor: David G. Hangauer, Jr.
  • Treatment of sleep disorders using CNS target modulators
    Patent number: 7189757
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: March 13, 2007
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J. M. Mignot
  • Protection against and treatment of hearing loss
    Patent number: 7129225
    Abstract: The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.
    Type: Grant
    Filed: October 19, 2002
    Date of Patent: October 31, 2006
    Assignees: The Research Foundation of State University of New York, Health Research Inc. (Roswell Park Division)
    Inventors: Thomas Nicotera, Donald Henderson, David G. Hangauer, Jr.
  • High throughput assay for identification of gene expression modifiers
    Patent number: 7083919
    Abstract: The present invention provides a method for screening of a large number of compounds for their ability to modulate the expression of genes. The method uses gene trap technology and comprises the steps of transfecting a population of cells with a gene-trap vector, sorting cells according to their level of fluorescence, distributing sorted cells into pools and expanding the pools to obtain a sufficient number of cells representing each trapped gene to permit distinction of the effect of a test compound over controls, exposing the cells to the test compounds and identifying compounds which alter the fluorescence distribution pattern of cells using FACS analysis.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: August 1, 2006
    Assignee: The Research Foundation of State University of New York
    Inventors: Steven C. Pruitt, David G. Hangauer, Carleton C. Stewart, Lawrence Mark Mielnicki
  • Method for designing protein kinase inhibitors
    Patent number: 7070936
    Abstract: The present invention provides a method for identifying inhibitors of protein kinases. Methods are also provided for inhibiting protein kinase activity. Specific non-peptide protein tyrosine kinase inhibitor are provided. The protein kinases produced using the method of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, or immune system activity.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: July 4, 2006
    Assignee: The Research Foundation of State University of New York
    Inventors: David G. Hangauer, Jr., Thomas H. Marsilje, Karen L. Milkiewicz
  • Protein kinase and phosphatase inhibitors and methods for designing them
    Patent number: 7005445
    Abstract: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.
    Type: Grant
    Filed: October 19, 2002
    Date of Patent: February 28, 2006
    Assignee: The Research Foundation of State University of New York
    Inventors: David G. Hangauer, Jr., Moustafa E. El-Araby, Karen L. Milkiewicz
  • CNS target modulators
    Publication number: 20040142972
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.
    Type: Application
    Filed: December 4, 2003
    Publication date: July 22, 2004
    Applicant: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J.M. Mignot
  • Protection against and treatment of hearing loss
    Publication number: 20040019015
    Abstract: The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.
    Type: Application
    Filed: October 19, 2002
    Publication date: January 29, 2004
    Inventors: Thomas Nicotera, Donald Henderson, David G. Hangauer
  • Treatment of sleeping disorders using CNS sleep target modulators
    Publication number: 20030232839
    Abstract: The invention is directed to compositions used for treating sleep disorders. In addition, the invention provides convenient methods of treatment of a sleep disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of ester derivatized trazodone compounds for the treatment of sleep disorders.
    Type: Application
    Filed: January 21, 2003
    Publication date: December 18, 2003
    Applicant: Hypnion, Inc.
    Inventors: David G. Hangauer, Harry Jefferson Leighton, Dale M. Edgar
  • Treatment of CNS disorders using CNS target modulators
    Publication number: 20030187021
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.
    Type: Application
    Filed: October 16, 2002
    Publication date: October 2, 2003
    Applicant: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J.M. Mignot
  • Protein kinase and phosphatase inhibitors and methods for designing them
    Publication number: 20030166615
    Abstract: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.
    Type: Application
    Filed: October 19, 2002
    Publication date: September 4, 2003
    Inventors: David G. Hangauer, Moustafa E. El-Araby, Karen L. Milkiewicz
  • High throughput assay for identification of gene expression modifiers
    Publication number: 20020164636
    Abstract: The present invention provides a method for screening of a large number of compounds for their ability to modulate the expression of genes. The method uses gene trap technology and comprises the steps of transfecting a population of cells with a gene-trap vector, sorting cells according to their level of fluorescence, distributing sorted cells into pools and expanding the pools to obtain a sufficient number of cells representing each trapped gene to permit distinction of the effect of a test compound over controls, exposing the cells to the test compounds and identifying compounds which alter the fluorescence distribution pattern of cells using FACS analysis.
    Type: Application
    Filed: May 6, 2002
    Publication date: November 7, 2002
    Inventors: Steven C. Pruitt, David G. Hangauer, Carleton C. Stewart, Lawrence Mark Mielnicki
  • Carboxyalkyl urea compounds and derivatives thereof useful as angiotensin converting enzyme inhibitors and as antihypertensives
    Patent number: 4866087
    Abstract: Carboxyalkyl urea compounds and derivatives thereof are disclosed which are useful as angiotensin converting enzyme (ACE) inhibitors and as antihypertensives. These compounds and derivatives are represented by the general formula: ##STR1## An illustrative specie falling within this general formula is:N-(2-carboxy-4-phenylbutyl-N-isopropylaminocarbonyl-L-tryptophan.
    Type: Grant
    Filed: June 27, 1983
    Date of Patent: September 12, 1989
    Assignee: Merck & Co., Inc.
    Inventors: William J. Greenlee, David G. Hangauer, Jr., Arthur A. Patchett
  • Antihypertensive proline derivatives
    Patent number: 4402969
    Abstract: The invention relates to urea compounds which are useful as antihypertensives.
    Type: Grant
    Filed: January 21, 1982
    Date of Patent: September 6, 1983
    Assignee: Merck & Co., Inc.
    Inventors: William J. Greenlee, David G. Hangauer, Jr., Arthur A. Patchett